Content about Anatomy

November 1, 2012

Procter & Gamble Prestige’s The Art of Shaving grooming brand is joining in the fight against cancers affecting men, by teaming up with global men’s health charity Movember.

NEW YORK – Procter & Gamble Prestige’s The Art of Shaving grooming brand is joining in the fight against cancers affecting men, by teaming up with global men’s health charity Movember.

October 26, 2012

The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the second new drug in two months for a form of leukemia, the agency said Friday.

The FDA announced the approval of Teva Pharmaceutical Industries' Synribo (omacetaxine mepesuccinate) for chronic myelogenous leukemia, or CML, a disease that the National Institutes of Health expects will be diagnosed in more than 5,400 people this year. The drug is intended for patients whose disease has progressed after treatment with at least two drugs of a class used to treat the disease.

October 18, 2012

Epilady USA has collaborated with Sharper Image to develop an all-in-one Sharper Image Total Body Hair Removal System and is set to launch a new Sharper Image Bikini Trimmer in the near future, the company has announced.

NEW YORK — Epilady USA has collaborated with Sharper Image to develop an all-in-one Sharper Image Total Body Hair Removal System and is set to launch a new Sharper Image Bikini Trimmer in the near future, the company has announced.

October 17, 2012

Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy.

LONDON — Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy

An immunomodulatory agent has an effect on the immune system. 

October 12, 2012

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.

October 12, 2012

Lansinoh Laboratories on Friday announced the launch of the new Lansinoh Affinity Pro Double Electric Breast Pump, featuring three customizable pumping styles that can help moms maximize milk flow and comfort to enhance breastfeeding success.

 WASHINGTON — Lansinoh Laboratories on Friday announced the launch of the new Lansinoh Affinity Pro Double Electric Breast Pump, featuring three customizable pumping styles that can help moms maximize milk flow and comfort to enhance breastfeeding success. The new Lansinoh Affinity Pro pump was recognized as a finalist in the Juvenile Products Manufacturers Association 2012 Innovation Awards, the company reported. 

October 11, 2012

Mission Pharmacal has launched what it called an alternative to pill therapy for osteoporosis.

SAN ANTONIO — Mission Pharmacal has launched what it called an alternative to pill therapy for osteoporosis.

The drug maker announced Thursday the availability of Binosto (alendronate sodium) effervescent tablets for buffered oral solution in pharmacies. The drug is used to treat osteoporosis in postmenopausal women and increase bone mass in men with the condition.

October 10, 2012

Mylan has settled a patent infringement suit over a drug used to treat respiratory diseases, Mylan said.

PITTSBURGH — Mylan has settled a patent infringement suit over a drug used to treat respiratory diseases, Mylan said.

The generic drug maker said it resolved a patent litigation suit filed by Shionogi and Cima Labs over prednisolone sodium phosphate orally disintegrating tablets, a generic version of Orapred ODT. Mylan is hoping to market its generic version of the drug in the 10-mg, 15-mg and 30-mg strengths. The drug is used to treat asthma and certain allergic conditions.

October 9, 2012

Depilatories are experiencing double-digit growth, according to 52-week data ended Sept. 9 from SymphonyIRI Group, and Nad’s is looking to snap up some sales with its new Nose Wax for men and women.

GARDEN GROVE, Calif. — Depilatories are experiencing double-digit growth, according to 52-week data ended Sept. 9 from SymphonyIRI Group, and Nad’s is looking to snap up some sales with its new Nose Wax for men and women. The DIY wax system is positioned as the world’s first nose wax. It is applied with a special Safetip applicator that is designed to target the hair around the edge of the nostril. Each package of Nad’s Nose Wax contains three treatment packs, a “moustache stencil” for men, post-wax calming wipes and antibacterial wipes.

October 9, 2012

Nail polish continues to be the rock star of the beauty world, and it shows no signs of slowing. A recent report by Packaged Facts, titled “The Nail Care Market in the U.S.,” addresses the robust growth of the nail care market and suggests “several intertwined factors are driving 
the market.”


Nail polish continues to be the rock star of the beauty world, and it shows no signs of slowing. A recent report by Packaged Facts, titled “The Nail Care Market in the U.S.,” addresses the robust growth of the nail care market and suggests “several intertwined factors are driving 
the market.”


October 3, 2012

A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

INDIANAPOLIS — A drug marketed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly reduced blood sugar in elderly patients with Type 2 diabetes and in adults with diabetic nephropathy, according to results of three studies presented at a diabetes meeting in Berlin.

October 1, 2012

Reckitt Benckiser recently named Tiffany McLaud to the position of consumer healthcare marketing director.

PARSIPPANY, N.J. — Reckitt Benckiser recently named Tiffany McLaud to the position of consumer healthcare marketing director. McLaud joins RB from Pfizer Consumer Healthcare where she held a number of senior positions, most recently as senior director of U.S. dietary supplements.

As RB's healthcare marketing director, McLaud will oversee the company's healthcare portfolio, including Mucinex, Delsym and Cepacol.

September 21, 2012

The Food and Drug Administration has approved a new usage for an Amgen drug, the drug maker said.

THOUSAND OAKS, Calif. — The Food and Drug Administration has approved a new usage for an Amgen drug, the drug maker said.

The biotech manufacturer announced the FDA approval of Prolia (denosumab) to increase bone mass in men with osteoporosis who are at high risk for fracture. The drug already was approved for osteoporosis in postmenopausal women.

September 19, 2012

Helen of Troy has announced the availability of Beauty Chic, a new line of home spa products for feet, face and skin.

EL PASO, Texas — Helen of Troy has announced the availability of Beauty Chic, a new line of home spa products for feet, face and skin.

The Beauty Chic line consists of a manicure and pedicure kit, nail dryer, facial sauna, foot bath massager, paraffin bath, bath spa kit and a facial spa kit. All of the spa products were designed to give women the same results they would receive in a salon.

September 18, 2012

Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow.

LOS ANGELES — Earlier this summer Hyland’s introduced its Leg Cramps Ointment to complement its line of homeopathic Leg Cramps tablets. Expect the leg cramp market to grow. According to one study, about half of all seniors suffer from leg cramps — they’re more common in women (56%) than men (40%). And two drug classes with strong links to leg cramps include diuretics and the inhaled long-acting B2-agonists 
(e.g., Advair, Serevent, Symbicort).

September 18, 2012

L’Oréal Paris is looking to make the hair color aisle at mass easier to shop and is eliminating the guesswork out of choosing the right hair color shade with its new “My L’Oréal Colorist” mobile app, which serves as a personal color consultant.


NEW YORK — L’Oréal Paris is looking to make the hair color aisle at mass easier to shop and is eliminating the guesswork out of choosing the right hair color shade with its new “My L’Oréal Colorist” mobile app, which serves as a personal color consultant.


September 13, 2012

Hair removal brand Nad's has announced the launch of Nad's nose wax for men and women, a complete do-it-yourself nose wax system for removing nose hair.

LOS ANGELES — Hair removal brand Nad's has announced the launch of Nad's nose wax for men and women, a complete do-it-yourself nose wax system for removing nose hair.

Containing chamomile and aloe, Nad’s nose wax is applied with the Nad’s Safetip applicator that is designed to target the hair around the edge of the nostril, only removing hairs that are sticking out or easily noticed. The specially formulated wax also can be used to remove blackheads from the nose’s surface.

September 12, 2012

After three years in development, HeadBlade is introducing its most innovative design since the original HeadBlade Classic in 1999. Enter the HeadBlade ATX All Terrain Razor.

NEW YORK — After three years in development, HeadBlade is introducing its most innovative design since the original HeadBlade Classic in 1999. Enter the HeadBlade ATX All Terrain Razor.

The new HeadBlade ATX All Terrain Razor is now available online and will hit retail stores in early 2013. The manufacturer's suggested retail price for ATX is $15 at headblade.com; the manufacturer's suggested retail price for HB4 Blade Refills is $11.97 at headblade.com.

September 4, 2012

According to a Food and Drug Administration post Friday, the FDA's Nonprescription Drugs Advisory Committee will be meeting Nov. 9 regarding the partial switch application from prescription to over the counter of Oxytrol (oxybutynin transdermal system), as submitted by MSD Consumer.

SILVER SPRING, Md. — According to a Food and Drug Administration post Friday, the FDA's Nonprescription Drugs Advisory Committee will be meeting Nov. 9 regarding the partial switch application from prescription to over the counter of Oxytrol (oxybutynin transdermal system) submitted by MSD Consumer. The proposed OTC product would be called Oxytrol for Women and would be indicated for the treatment of overactive bladder in women.

The prescription form of Oxytrol is licensed by Watson Pharma.

September 4, 2012

Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

HAYWARD, Calif. — Generic drug maker Impax Labs has settled with a subsidiary of Sanofi regarding generic versions of two drugs for dialysis patients, Impax said Tuesday.

Impax announced a settlement with Genzyme concerning generic versions of Renvela (sevelamer carbonate) 800 mg tablets and 2.4 g and 0.8 g oral suspension and Renagel (sevelamer hydrochloride) tablets in the 400 mg and 800 mg strengths.

September 4, 2012

Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

INDIANPOLIS — Lilly Diabetes announced that it has launched a new mobile application designed for caregivers and healthcare providers who support people with Type 1 diabetes.

The Lilly Glucagon mobile app is an interactive tool designed to teach caregivers how to use severe hypoglycemia treatment Glucagon (1-mg) for injection through simulated practice, thus helping caregivers better understand Glucagon's role in diabetes management. The Lilly Glucagon mobile app includes:

  • Information about severe hypoglycemia and Glucagon;

August 30, 2012

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

August 29, 2012

A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

WASHINGTON — A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

According to published reports, the panel voted 15-2 that the benefits of Humira outweighed the risks in treating ulcerative colitis. However, the panel asked Abbott to conduct more studies upon Humira's approval.

August 23, 2012

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

SPRING HOUSE, Pa. — A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

August 15, 2012

The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

Wockhardt, based in Mumbai, India, announced the approval of alfuzosin hydrochloride extended-release tablets in the 10-mg strength, which is designed to treat enlarged prostate, also known as benign prostatic hyperplasia.

The drug is a generic version of Sanofi's Uroxatral. Various versions of the drug have sales of about $81.5 million, according to IMS Health.